Human Immunology News Volume 3.30 | Aug 4 2015

    0
    39
    Human Immunology News 3.30 August 4, 2015

    Human Immunology News

         In this issue: Publications | Reviews | Science News | Industry News | Policy News | Events | Jobs
    Like Us on Facebook  HIN on Twitter

     
    TOP STORY
    Protein Tyrosine Phosphatase PTPRS Is an Inhibitory Receptor on Human and Murine Plasmacytoid Dendritic Cells
    Scientists report that within the human immune system, receptor protein tyrosine phosphatase sigma (PTPRS) is expressed specifically on plasmacytoid dendritic cells (pDCs). Surface PTPRS was rapidly downregulated after pDC activation, and only PTPRS− pDCs produced interferon-α. [Immunity] Abstract | Graphical Abstract
    A New System for High-Throughput Cell Isolation Directly from Whole Blood

     
    PUBLICATIONS (Ranked by impact factor of the journal)
    Identification of Resolvin D2 Receptor Mediating Resolution of Infections and Organ Protection
    Using an unbiased G protein–coupled receptor-β-arrestin–based screening and functional sensing systems, researchers identified a receptor for resolvin D2, namely GPR18, that is expressed on human leukocytes, including polymorphonuclear neutrophils, monocytes, and macrophages. [J Exp Med] Abstract | Editorial

    Foxp3+ Regulatory T Cells Are Expanded in Severe Atopic Dermatitis Patients
    Scientists measured circulating regulatory T cell (Treg) frequencies of adult patients and detected a positive correlation with disease severity. Subsequent surface marker analysis revealed higher frequencies of CD45RA+CCR7 tissue-homing Tregs in the patient group with a tendency of reduced expression of CD39 compared to healthy donors, a marker for the highly suppressive TREM subtype. [Allergy] Abstract

    Transcriptional Profiling of Macrophages Derived from Monocytes and iPS Cells Identifies a Conserved Response to LPS and Novel Alternative Transcription
    Investigators compared the transcriptomes of naïve and lipopolysaccharide (LPS) stimulated monocyte-derived macrophages and macrophages differentiated from human induced pluripotent stem cells (iPS) using RNA-Seq. [Sci Rep] Full Article

    Exclusive Transduction of Human CD4+ T Cells upon Systemic Delivery of CD4-Targeted Lentiviral Vectors
    Researchers describe novel lentiviral vectors (CD4-LV) that have been rendered selective for human or simian CD4+ cells by surface engineering. When applied to PBMCs, CD4-LV transduced CD4+ but not CD4 cells. [J Immunol] Abstract

    Regulatory B Cells in CVID Patients Fail to Suppress Multifunctional IFN-γ+TNF-α+CD4+ T Cells Differentiation
    The authors demonstrate a relationship in the production of pro-inflammatory Th1 cytokines and regulatory B cells producing IL-10 between common variable immunodeficiency (CVID) patients and healthy controls. [Clin Immunol] Abstract

    The Crohn’s Disease-Associated Polymorphism in ATG16L1 (rs2241880) Reduces SHIP Gene Expression and Activity in Human Subjects
    Scientists analyzed SH2 domain-containing inositolpolyphosphate 5′-phosphatase (SHIP) mRNA expression and activity in biopsies and peripheral blood mononuclear cells (PBMCs) from control and treatment-naive subjects with ileal Crohn’s disease (CD), and demonstrated that SHIP mRNA and activity were lower in hematopoietic cells in ileal biopsies and PBMCs from subjects with CD. [Genes Immun] Abstract

    Differential Influence of Maternal and Fetal Pregnancy Factors on the In Vitro Induction of Human Regulatory T Cells: A Preliminary Study
    Given the important role of regulatory T cells (Treg) for successful pregnancy, the ability of soluble maternal and fetal pregnancy factors to induce human Treg was investigated. [Swiss Med Wkly] Full Article

    Individuality and Variation of Personal Regulomes in Primary Human T Cells
    Investigators applied Assay of Transposase Accessible Chromatin with sequencing to map chromatin accessibility in primary CD4+ T cells isolated from standard blood draws from 12 healthy volunteers over time, from cancer patients, and during T-cell activation. Over 4,000 predicted regulatory elements showed reproducible variation in accessibility between individuals. [Cell Syst]
    Full Article | Graphical Abstract | Press Release

    Subscribe to our sister publications: Immunology of Infectious Disease News & Immune Regulation News!

    Only One of These Antibodies Will Work for Your Cell Analysis. We Take the Guesswork Out of Finding the Right

     
    REVIEWS
    Molecular Characterization of HCMV-Specific Immune Responses: Parallels between CD8+ T Cells, CD4+ T Cells and NK Cells
    The authors aim to highlight the most recent developments in human cytomegalovirus (HCMV)-specific CD8+ T-cell differentiation, maintenance, tissue distribution, metabolism and function. [Eur J Immunol] Abstract

    Visit our reviews page to see a complete list of reviews in the human immunology research field.

    Save 10% on your pass to Cell & Gene Therapy Europe!

     
    SCIENCE NEWS
    Immunicum Presents Continued Improvement in Phase I/II Survival Data for INTUVAX-Treated Renal Cancer Patients
    Immunicum reports updated survival data from the company’s Phase I/II study in patients with metastatic renal cancer treated with the cancer vaccine INTUVAX. [Immunicum AB] Press Release

    From our sponsor: Learn how HLA labs save resources with RoboSep™. Watch the webinar.

     
    INDUSTRY NEWS
    La Jolla Institute Announces Affiliation with UC San Diego Health
    The La Jolla Institute for Allergy and Immunology announced an official affiliation agreement with the University of California, San Diego Health System (UCSD). The multi-year agreement with UCSD will facilitate joint faculty appointments, enhance the range and depth of collaboration between the two organizations, and promote closer integration between basic immunology research and clinical medicine to speed the development of treatments for diseases of the immune system. [La Jolla Institute for Allergy and Immunology] Press Release

    Formula Pharmaceuticals and the Max Delbrück Center for Molecular Medicine Enter into an Exclusive Licensing Agreement and Strategic Collaboration to Develop C.I.K. CAR™ Immunotherapies
    Formula Pharmaceuticals, Inc. and the Max Delbrück Center for Molecular Medicine in the Helmholtz Association (MDC) announced the establishment of an exclusive licensing agreement and strategic collaboration for the development of Cytokine Induced Killer (C.I.K.) cell-based chimeric antigen receptor (CAR) immunotherapies, using MDC’s proprietary SB100X transposase, a component of the non-viral, Sleeping Beauty transposon-based gene transfer system. [Formula Pharmaceuticals, Inc.] Press Release

    VF Funds New Study: Immune Regulation by IL-6 in Giant Cell Arteritis
    The Vasculitis Foundation (VF) is funding a new, one-year study led by principal investigator, Jonathan Choy, Ph.D., from Simon Fraser University. The $50,000 study, “Immune regulation by IL-6 in giant cell arteritis”, will focus on the way in which cytokine IL-6 activates T cell responses in giant cell arteritis [Vasculitis Foundation (Newswise, Inc.)] Press Release

    Immunomedics Announces Orphan Drug Designation for Veltuzumab for the Treatment of Immune Thrombocytopenia
    Immunomedics, Inc. announced that the Office of Orphan Products Development of the U.S. Food and Drug Administration has granted orphan status for the use of veltuzumab, the company’s humanized anti-CD20 antibody, for the treatment of immune thrombocytopenia. [Immunomedics, Inc. (GlobeNewswire, Inc.)] Press Release

    Sorrento In-Licenses Four Late-Stage Clinical Biobetter and Biosimilar Antibodies
    Sorrento Therapeutics, Inc. announced that it has entered into an exclusive licensing agreement to develop and commercialize multiple prespecified and undisclosed biosimilar or biobetter antibodies from Mabtech Limited, a holding company for premier antibody development and manufacturing companies in China. [Sorrento Therapeutics, Inc.] Press Release

    Arena Pharmaceuticals Initiates a Phase II Clinical Trial of APD334, its S1P1 Receptor Modulator for Autoimmune Diseases
    Arena Pharmaceuticals, Inc. announced the initiation of patient screening in a Phase II proof-of-concept clinical trial of APD334 in ulcerative colitis. Discovered by Arena, APD334 is an oral, investigational, Sphingosine 1-Phosphate Subtype 1 (S1P1) receptor modulator with therapeutic potential in ulcerative colitis as well as other autoimmune diseases. [Arena Pharmaceuticals, Inc.] Press Release

     
    POLICY NEWS
    National Institutes of Health (United States)

    Food and Drug Administration (United States)

    Center for Biologics Evaluation and Research (United States)

    European Medicines Agency (European Union)

    Medicines and Healthcare Products Regulatory Agency (United Kingdom)

    Therapeutic Goods Administration (Australia)

     
    EVENTS
    NEW Cell & Gene Therapy Europe
    September 29-30, 2015
    Barcelona, Spain

    Visit our events page to see a complete list of events in the human immunology community.

     
    JOB OPPORTUNITIES
    NEW Faculty Positions – Stem Cell/Immunology/Medical Virology (Hallym University Medical Center)

    Research Associate – Cell Separation (STEMCELL Technologies Inc.)

    Scientific Marketing Specialist – Immunology (STEMCELL Technologies Inc.)

    Postdoctoral Fellow – Biotechnology (Qu Biologics Inc.)

    Harry Eagle Scholar Awards for Postdoctoral Candidates (Albert Einstein College of Medicine of Yeshiva University)

    Postdoctoral Positions – Cancer Research (Rutgers University)

    Research Associate – Cell Biology (Editas Medicine)

    Senior Research Associate (Editas Medicine)

    Postdoctoral Researcher – Immunology (New York University School of Medicine)

    Postdoctoral Fellow – Immunology (Cellectis Inc.)

    Postdoctoral Fellowship – Immunology (Huazhong University of Science and Technology)

    Postdoctoral Position – Translational Immunology (University of Utah School of Medicine)

    Postdoctoral Fellow – Antibody Engineering/Immuno-Oncology (California Institute for Biomedical Research)


    Recruit Top Talent: Reach more than 60,000 potential candidates by posting your organization’s career opportunities on the Connexon Creative Job Board at no cost.

     

    Have we missed an important article or publication in Human Immunology News? Click here to submit!

    Comments or suggestions? Submit your feedback here

    Learn more about Human Immunology News: Archives | Events | Contact Us